-
Something wrong with this record ?
Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction)
S. Brugaletta, T. Gori, AF. Low, P. Tousek, E. Pinar, J. Gomez-Lara, G. Scalone, E. Schulz, MY. Chan, V. Kocka, J. Hurtado, JA. Gomez-Hospital, T. Münzel, CH. Lee, A. Cequier, M. Valdés, P. Widimsky, PW. Serruys, M. Sabaté,
Language English Country United States
Document type Comparative Study, Journal Article, Multicenter Study, Observational Study, Research Support, Non-U.S. Gov't
- MeSH
- Time Factors MeSH
- Databases, Factual MeSH
- Adult MeSH
- Myocardial Infarction diagnosis mortality therapy MeSH
- Kaplan-Meier Estimate MeSH
- Cardiovascular Agents administration & dosage MeSH
- Percutaneous Coronary Intervention adverse effects instrumentation mortality MeSH
- Coronary Thrombosis etiology MeSH
- Metals * MeSH
- Middle Aged MeSH
- Humans MeSH
- Logistic Models MeSH
- Proportional Hazards Models MeSH
- Prosthesis Design MeSH
- Recurrence MeSH
- Retrospective Studies MeSH
- Risk Factors MeSH
- Aged MeSH
- Sirolimus administration & dosage analogs & derivatives MeSH
- Drug-Eluting Stents * MeSH
- Propensity Score MeSH
- Absorbable Implants * MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Observational Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
OBJECTIVES: The purpose of this study was to compare the 1-year outcome between bioresorbable vascular scaffold (BVS) and everolimus-eluting metallic stent (EES) in ST-segment elevation myocardial infarction (STEMI) patients. BACKGROUND: The Absorb BVS (Abbott Vascular, Santa Clara, California) is a polymeric scaffold approved for treatment of stable coronary lesions. Limited and not randomized data are available on its use in ST-segment elevation myocardial infarction (STEMI) patients. METHODS: This study included 290 consecutive STEMI patients treated by BVS, compared with either 290 STEMI patients treated with EES or 290 STEMI patients treated with bare-metal stents (BMS) from the EXAMINATION (A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-segment Elevation Myocardial Infarction) trial, by applying propensity score matching. The primary endpoint was a device-oriented endpoint (DOCE), including cardiac death, target vessel myocardial infarction, and target lesion revascularization, at 1-year follow-up. Device thrombosis, according to the Academic Research Consortium criteria, was also evaluated. RESULTS: The cumulative incidence of DOCE did not differ between the BVS and EES or BMS groups either at 30 days (3.1% vs. 2.4%, hazard ratio [HR]: 1.31 [95% confidence interval (CI): 0.48 to 3.52], p = 0.593; vs. 2.8%, HR: 1.15 [95% CI: 0.44 to 2.30], p = 0.776, respectively) or at 1 year (4.1% vs. 4.1%, HR: 0.99 [95% CI: 0.23 to 4.32], p = 0.994; vs. 5.9%, HR: 0.50 [95% CI: 0.13 to 1.88], p = 0.306, respectively). Definite/probable BVS thrombosis rate was numerically higher either at 30 days (2.1% vs. 0.3%, p = 0.059; vs. 1.0%, p = 0.324, respectively) or at 1 year (2.4% vs. 1.4%, p = 0.948; vs. 1.7%, p = 0.825, respectively), as compared with EES or BMS. CONCLUSIONS: At 1-year follow-up, STEMI patients treated with BVS showed similar rates of DOCE compared with STEMI patients treated with EES or BMS, although rate of scaffolds thrombosis, mostly clustered in the early phase, was not negligible. Larger studies with longer follow-up are needed to confirm our findings.
Cardiology Department Interventional Cardiology Unit Virgen de la Arrixaca Hospital Murcia Spain
Institute of Cardiology Hospital of Bellvitge Barcelona Spain
Thoraxcenter Erasmus University Medical Center Rotterdam the Netherlands
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15031489
- 003
- CZ-PrNML
- 005
- 20190607100834.0
- 007
- ta
- 008
- 151005s2015 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jcin.2014.10.005 $2 doi
- 035 __
- $a (PubMed)25616924
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Brugaletta, Salvatore $u Thorax Institute, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. Electronic address: sabrugal@clinic.ub.es.
- 245 10
- $a Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction) / $c S. Brugaletta, T. Gori, AF. Low, P. Tousek, E. Pinar, J. Gomez-Lara, G. Scalone, E. Schulz, MY. Chan, V. Kocka, J. Hurtado, JA. Gomez-Hospital, T. Münzel, CH. Lee, A. Cequier, M. Valdés, P. Widimsky, PW. Serruys, M. Sabaté,
- 520 9_
- $a OBJECTIVES: The purpose of this study was to compare the 1-year outcome between bioresorbable vascular scaffold (BVS) and everolimus-eluting metallic stent (EES) in ST-segment elevation myocardial infarction (STEMI) patients. BACKGROUND: The Absorb BVS (Abbott Vascular, Santa Clara, California) is a polymeric scaffold approved for treatment of stable coronary lesions. Limited and not randomized data are available on its use in ST-segment elevation myocardial infarction (STEMI) patients. METHODS: This study included 290 consecutive STEMI patients treated by BVS, compared with either 290 STEMI patients treated with EES or 290 STEMI patients treated with bare-metal stents (BMS) from the EXAMINATION (A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-segment Elevation Myocardial Infarction) trial, by applying propensity score matching. The primary endpoint was a device-oriented endpoint (DOCE), including cardiac death, target vessel myocardial infarction, and target lesion revascularization, at 1-year follow-up. Device thrombosis, according to the Academic Research Consortium criteria, was also evaluated. RESULTS: The cumulative incidence of DOCE did not differ between the BVS and EES or BMS groups either at 30 days (3.1% vs. 2.4%, hazard ratio [HR]: 1.31 [95% confidence interval (CI): 0.48 to 3.52], p = 0.593; vs. 2.8%, HR: 1.15 [95% CI: 0.44 to 2.30], p = 0.776, respectively) or at 1 year (4.1% vs. 4.1%, HR: 0.99 [95% CI: 0.23 to 4.32], p = 0.994; vs. 5.9%, HR: 0.50 [95% CI: 0.13 to 1.88], p = 0.306, respectively). Definite/probable BVS thrombosis rate was numerically higher either at 30 days (2.1% vs. 0.3%, p = 0.059; vs. 1.0%, p = 0.324, respectively) or at 1 year (2.4% vs. 1.4%, p = 0.948; vs. 1.7%, p = 0.825, respectively), as compared with EES or BMS. CONCLUSIONS: At 1-year follow-up, STEMI patients treated with BVS showed similar rates of DOCE compared with STEMI patients treated with EES or BMS, although rate of scaffolds thrombosis, mostly clustered in the early phase, was not negligible. Larger studies with longer follow-up are needed to confirm our findings.
- 650 12
- $a vstřebatelné implantáty $7 D020341
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a kardiovaskulární látky $x aplikace a dávkování $7 D002317
- 650 _2
- $a koronární trombóza $x etiologie $7 D003328
- 650 _2
- $a databáze faktografické $7 D016208
- 650 12
- $a stenty uvolňující léky $7 D054855
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a logistické modely $7 D016015
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a kovy $7 D008670
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a infarkt myokardu $x diagnóza $x mortalita $x terapie $7 D009203
- 650 _2
- $a koronární angioplastika $x škodlivé účinky $x přístrojové vybavení $x mortalita $7 D062645
- 650 _2
- $a tendenční skóre $7 D057216
- 650 _2
- $a proporcionální rizikové modely $7 D016016
- 650 _2
- $a protézy - design $7 D011474
- 650 _2
- $a recidiva $7 D012008
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a sirolimus $x aplikace a dávkování $x analogy a deriváty $7 D020123
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a pozorovací studie $7 D064888
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Gori, Tommaso $u Medizinische Klinik und Poliklinik für Kardiologie, Angiologie und innere Intensivmedizin, Mainz, Germany.
- 700 1_
- $a Low, Adrian F $u Cardiac Department, National University Heart Centre Singapore, National University Health System, Singapore.
- 700 1_
- $a Tousek, Petr $u Cardiocenter, Third Faculty of Medicine, Charles University in Prague, University Hospital Kralovske Vinohrady, Prague, Czech Republic.
- 700 1_
- $a Pinar, Eduardo $u Cardiology Department, Interventional Cardiology Unit, Virgen de la Arrixaca Hospital, Murcia, Spain.
- 700 1_
- $a Gomez-Lara, Josep $u Institute of Cardiology, Hospital of Bellvitge, Barcelona, Spain.
- 700 1_
- $a Scalone, Giancarla $u Thorax Institute, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
- 700 1_
- $a Schulz, Eberhard $u Medizinische Klinik und Poliklinik für Kardiologie, Angiologie und innere Intensivmedizin, Mainz, Germany.
- 700 1_
- $a Chan, Mark Y $u Cardiac Department, National University Heart Centre Singapore, National University Health System, Singapore.
- 700 1_
- $a Kocka, Viktor $u Cardiocenter, Third Faculty of Medicine, Charles University in Prague, University Hospital Kralovske Vinohrady, Prague, Czech Republic.
- 700 1_
- $a Hurtado, Jose $u Cardiology Department, Interventional Cardiology Unit, Virgen de la Arrixaca Hospital, Murcia, Spain.
- 700 1_
- $a Gomez-Hospital, Juan Antoni $u Institute of Cardiology, Hospital of Bellvitge, Barcelona, Spain.
- 700 1_
- $a Münzel, Thomas $u Medizinische Klinik und Poliklinik für Kardiologie, Angiologie und innere Intensivmedizin, Mainz, Germany.
- 700 1_
- $a Lee, Chi-Hang $u Cardiac Department, National University Heart Centre Singapore, National University Health System, Singapore.
- 700 1_
- $a Cequier, Angel $u Institute of Cardiology, Hospital of Bellvitge, Barcelona, Spain.
- 700 1_
- $a Valdés, Mariano $u Cardiology Department, Interventional Cardiology Unit, Virgen de la Arrixaca Hospital, Murcia, Spain.
- 700 1_
- $a Widimsky, Petr $u Cardiocenter, Third Faculty of Medicine, Charles University in Prague, University Hospital Kralovske Vinohrady, Prague, Czech Republic.
- 700 1_
- $a Serruys, P. W., $d 1947- $7 xx0236888 $u Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands.
- 700 1_
- $a Sabaté, Manel $u Thorax Institute, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
- 773 0_
- $w MED00186218 $t JACC. Cardiovascular interventions. Cardiovascular interventions $x 1876-7605 $g Roč. 8, č. 1 Pt B (2015), s. 189-97
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25616924 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20151005 $b ABA008
- 991 __
- $a 20190607101012 $b ABA008
- 999 __
- $a ok $b bmc $g 1092365 $s 914615
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 8 $c 1 Pt B $d 189-97 $i 1876-7605 $m JACC. Cardiovascular interventions $n JACC Cardiovasc Interv $x MED00186218 $o Cardiovascular interventions
- LZP __
- $a Pubmed-20151005
